https://getorexin.com/ Dated changes to the orexin receptor agonist clinical pipeline. en Sun, 09 Aug 2026 12:00:00 GMT https://getorexin.com/changelog/ 2026-08-09-0 Sun, 09 Aug 2026 12:00:00 GMT Roughly seven hundred papers mentioning orexin are published every year. Until now this site cited almost none of them, which left a real gap: a sponsor announcement tells you what a company decided, and a paper tells you what the data showed. The new research page carries the papers worth a reader's time, each with a note in plain language on what it found and what it does not show. Eight papers to start, grouped by what they are about: why the orexin neurons die, what the system does, metabolism, diagnosis, and uses outside narcolepsy. Two more went onto program pages instead, where they belong. Alixorexton's first peer-reviewed human data appeared in the Journal of Sleep Research five days ago, a phase 1b crossover in 27 patients across all three conditions the drug is aimed at. Oveporexton gained a rat study measuring whether this class of drug directly causes the excess saliva that patients report. The selection is done by hand, and the refusals matter as much as the inclusions. A Cell Metabolism paper on brown fat and lifespan turned up in the search and was left out because orexin appears in it only in passing. A Nature Reviews Drug Discovery news item was left out because it summarises a result this site already reports from the primary source. A Science paper on orexin and empathy was included with the word mice in the first line of its note. Finding the candidates is now scripted against Europe PMC, and the same run re-checks every paper already cited here for retraction and correction notices, so a withdrawn paper does not sit on the site unmarked. The script proposes; it does not publish. Judgement about which paper matters gets published under a name. The list is also available as research.json under CC BY 4.0, alongside the pipeline data. https://getorexin.com/changelog/ 2026-08-04-1 Tue, 04 Aug 2026 12:00:00 GMT Harmony Biosciences reported the first human data for BP-205, an OX2R-selective agonist, on 4 August 2026. It is now tracked here as the tenth active program. The compound is not registered on ClinicalTrials.gov under any name, so the registry sweep that maintains the rest of this site could not have found it. It surfaced in the company’s 8-K, filed with the SEC the same day, with the results deck attached as an exhibit. That filing is the source cited on the page. The gap is worth stating plainly: registry-only monitoring misses compounds whose early trials run outside the US registry, and filings-only monitoring misses sponsors that do not file with the SEC. Takeda and Eisai are Japanese and file no 8-K. Both sources are needed, and neither is sufficient. https://getorexin.com/changelog/ 2026-08-04-2 Tue, 04 Aug 2026 12:00:00 GMT Each program page now lists every study on ClinicalTrials.gov that names the compound or its development code, with phase, recruitment status, enrolment and primary completion date. That is 44 studies across the nine active programs and the three discontinued ones, up from the 9 cited before. The registry data is refreshed mechanically rather than by hand, and published alongside the main dataset at /trials.json. ALKS 4510 and ALKS 7290 return no registry records; both are listed on Alkermes' pipeline page but have no public study. https://getorexin.com/changelog/ 2026-08-04-3 Tue, 04 Aug 2026 12:00:00 GMT Every program now has its own page with its trial registry IDs, sources and common questions. Five background explainers cover the drug class, narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, the agonist/antagonist distinction, and how this class compares to current treatments. The underlying dataset is published at /data.json and is free to use with attribution. https://getorexin.com/changelog/ 2026-08-04-4 Tue, 04 Aug 2026 12:00:00 GMT Eight programs previously flagged as needing re-checking were verified against ClinicalTrials.gov records and sponsor pipeline pages, and corrected where they were wrong. Notable corrections: cleminorexton moved to Phase 3 following the registrational study that opened 29 May 2026; ORX489 moved from IND-enabling to Phase 1; E2086 moved to Phase 2. TAK-360 stays at Phase 2 despite its extension study NCT07646678 carrying a Phase 2/3 registry label, because that study is not a pivotal efficacy trial. https://getorexin.com/changelog/ 2026-07-30-5 Thu, 30 Jul 2026 12:00:00 GMT Takeda's Q1 FY2026 earnings release confirmed the US application remains under review, with launch preparations underway for the second half of 2026. The PDUFA target remains a third-quarter window with no named day. https://getorexin.com/changelog/ 2026-07-22-6 Wed, 22 Jul 2026 12:00:00 GMT Chinese regulators approved oveporexton, brand name ORZEYFUL, for adults and adolescents aged 16 and over with narcolepsy type 1. It is the first oral OX2R-selective agonist approved in any country. https://getorexin.com/changelog/ 2026-06-24-7 Wed, 24 Jun 2026 12:00:00 GMT Centessa Pharmaceuticals became a wholly owned Eli Lilly subsidiary, moving cleminorexton, ORX142 and ORX489 into Lilly's portfolio. https://getorexin.com/changelog/ 2026-04-01-8 Wed, 01 Apr 2026 12:00:00 GMT Alkermes opened the Brilliance program: Study 302 and Study 304 in narcolepsy type 1, Study 303 in narcolepsy type 2. Vibrance-3 continues at Phase 2 in idiopathic hypersomnia.